What it's for (Indications)
- Linezolid (Example brand: Nezkil) is an oxazolidinone antibiotic indicated for the treatment of infections caused by susceptible Gram-positive bacteria.
- These indications include vancomycin-resistant Enterococcus faecium (VRE) infections, including cases with concomitant bacteremia.
- It is also approved for nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae, and for community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains) or Staphylococcus aureus (methicillin-susceptible strains).
- Furthermore, linezolid is indicated for complicated skin and skin structure infections, including diabetic foot infections without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae.
- For uncomplicated skin and skin structure infections, it is used when caused by Staphylococcus aureus (methicillin-susceptible strains) or Streptococcus pyogenes.
- It is imperative to conduct appropriate culture and susceptibility testing to guide antimicrobial therapy and ensure linezolid's suitability.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for linezolid varies based on the specific infection and patient population. For adult patients with vancomycin-resistant Enterococcus faecium infections, nosocomial pneumonia, or complicated skin and skin structure infections, the recommended dosage is 600 mg administered either intravenously or orally every 12 hours for a duration of 10 to 14 consecutive days. For community-acquired pneumonia, the recommended dosage is 600 mg intravenously or orally every 12 hours, typically for 10 to 14 consecutive days. For uncomplicated skin and skin structure infections, the recommended adult dosage is 400 mg orally every 12 hours for 10 to 14 consecutive days. Pediatric dosing must be individualized based on age, weight, and the severity of infection. No dosage adjustment is generally required for patients with renal impairment (including those undergoing hemodialysis or peritoneal dialysis) or hepatic impairment, although caution and close monitoring are advised in these populations. It is crucial to complete the entire prescribed course of therapy to ensure eradication of the pathogen and minimize the development of antibiotic resistance. |
Safety & Warnings
Common Side Effects
- Linezolid can induce a variety of side effects, ranging from common gastrointestinal disturbances to severe systemic complications.
- Frequently reported adverse reactions include nausea, vomiting, diarrhea, headache, insomnia, constipation, and dizziness.
- However, more serious and potentially life-threatening adverse effects necessitate careful monitoring.
- These include myelosuppression, manifesting as thrombocytopenia, anemia, leukopenia, and pancytopenia, which often requires weekly complete blood count monitoring, especially with treatment durations exceeding two weeks.
- Peripheral and optic neuropathy have been reported, primarily with prolonged use (typically greater than 28 days), potentially leading to irreversible vision loss.
- Lactic acidosis, a serious metabolic complication characterized by symptoms such as unexplained nausea, vomiting, abdominal pain, and hyperventilation, can occur and may be fatal.
- Serotonin syndrome is a significant risk when linezolid is co-administered with other serotonergic agents.
- Furthermore, Clostridioides difficile-associated diarrhea (CDAD) and colitis can develop during or after treatment, and seizures have also been reported.
- Patients experiencing any severe or persistent adverse effects should seek immediate medical attention.
Serious Warnings
- Black Box Warning: **SEROTONIN SYNDROME RISK:** Linezolid possesses weak, reversible, nonselective monoamine oxidase (MAO) inhibitory activity. There have been reports of serotonin syndrome associated with the co-administration of linezolid and serotonergic agents, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, bupropion, buspirone, opioid analgesics (e.g., fentanyl, tramadol), and triptans. Symptoms of serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., tremor, rigidity, myoclonus, hyperreflexia), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). **WARNINGS REGARDING CONCOMITANT DRUGS:** Concomitant administration of linezolid with any serotonergic agent is generally not recommended unless the patient is closely monitored for signs and symptoms of serotonin syndrome. If signs or symptoms of serotonin syndrome occur, discontinue linezolid and the concomitant serotonergic agent immediately and initiate supportive symptomatic treatment. In patients requiring urgent treatment with linezolid, and for whom the potential benefits are judged to outweigh the risks of serotonin syndrome, the serotonergic agent should be discontinued immediately, and the patient monitored for two weeks (or five half-lives of the serotonergic agent, whichever is shorter) or until symptoms resolve, whichever comes first, prior to initiating linezolid.
- Several critical warnings and precautions are associated with linezolid use.
- Myelosuppression, encompassing anemia, leukopenia, pancytopenia, and thrombocytopenia, has been reported.
- Therefore, complete blood counts (CBCs) should be monitored weekly, particularly in patients receiving linezolid for longer than two weeks, those with pre-existing myelosuppression, or individuals concurrently receiving other bone marrow suppressive agents.
- Peripheral and optic neuropathy have occurred, predominantly in patients treated for extended periods (typically >28 days); patients should be advised to report any visual changes or new sensory symptoms promptly.
- Lactic acidosis is a potentially fatal adverse event, and patients presenting with unexplained acidosis, nausea, vomiting, or abdominal pain should be thoroughly evaluated.
- Seizures have been reported, particularly in patients with a history of seizures or identified risk factors.
- Linezolid possesses weak, nonselective, reversible monoamine oxidase (MAO) inhibitory activity, necessitating caution with concomitant use of adrenergic and serotonergic agents due to the risk of hypertensive reactions and serotonin syndrome, respectively.
- Patients should also avoid consuming large quantities of tyramine-rich foods and beverages while on linezolid.
How it Works (Mechanism of Action)
Linezolid is a synthetic antibacterial agent belonging to the oxazolidinone class, demonstrating potent activity against a wide range of Gram-positive bacteria. Its unique mechanism of action involves the inhibition of bacterial protein synthesis. Specifically, linezolid binds to a site on the 23S ribosomal RNA of the 50S ribosomal subunit. This binding prevents the formation of the N-formylmethionyl-tRNA-ribosome complex, which is the crucial 70S initiation complex required for the translation process. By interfering with the very first step of protein synthesis, linezolid effectively halts the initiation phase, preventing the bacteria from producing essential proteins for growth and replication. This distinctive binding site differentiates it from other classes of antibiotics that target protein synthesis, contributing to its efficacy against many multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its action is primarily bacteriostatic against most susceptible organisms, though it exhibits bactericidal activity against some streptococcal strains.